Table 6 Clinical outcome of patients on targeted therapy based on genomics report.
Drug (No. of patients) | Type of cancer | Survival Outcome (1.5–2 years follow-up) | Clinical outcome | |
|---|---|---|---|---|
Alive | Succumbed to disease | |||
ICI(44) | Breast(n = 7); CUP(n = 2); FGT(n = 4); GIT(n = 11); GU(n = 3); HN(n = 8); HPB(n = 3); Lung(n = 6) | n = 27 | n = 17 | CR(n = 5); PR(n = 21); PD(n = 1) |
Platinum/PARP inhibitors (22) | Breast(n = 8); FGT(n = 8); GIT(n = 1); GU(n = 1); HN(n = 2); Lung(n = 2) | n = 18 | n = 3 | CR(n = 12); PR(n = 5); PD(n = 1) |
Other TKIs(15) | Breast(n = 7); CUP(n = 1); GIT(n = 3); HN(n = 4) | n = 10 | n = 5 | CR(n = 12); PR(n = 2); PD(n = 1) |
Anti Her2 agents(17) | Breast(n = 11); CUP(n = 2); GIT(n = 2); HN(n = 1); Lung(n = 1) | n = 12 | n = 5 | CR(n = 11); PR(n = 6) |
EGFR TKIs(21) | Lung(n = 21) | n = 18 | n = 3 | CR(n = 17); PR(n = 4) |
mTOR inhibitor(5) | Breast(n = 4); FGT(n = 1); | n = 3 | n = 2 | CR(n = 0); PR(n = 2); PD(n = 1) |
Alk inhibitor(4) | Breast(n = 1); Lung(n = 4) | n = 4 | n = 0 | CR(n = 3); PR(n = 1) |
Monoclonal antibodies (4) | GIT(n = 4) | n = 1 | n = 3 | PR(n = 1) |
Sotorasib(3) | Lung(n = 3) | n = 3 | n = 0 | CR(n = 2); PR(n = 1) |
CDK 4/6 inhibitor(1) | HN(n = 1) | n = 0 | n = 1 | NA |
FGF/FGFR inhibitor(1) | GU(n = 1) | n = 1 | n = 0 | PR(n = 1) |
